Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity and Safety of the Heterologous Prime-boost Immunization with an Adenovirus Type-5 Vector-based COVID-19 Vaccine (Ad5-nCoV) After Three-dose Priming with an Inactivated COVID-19 Vaccine in Adults Aged 18 Years and Above: a Randomized, Open-label, Parallel-controlled Clinical Trial

NCT05303584 is registered in ClinicalTrials.gov with Jiangsu Province Centers for Disease Control and Prevention as lead sponsor.

NCT NCT05303584
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05303584 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity and Safety of the Heterologous Prime-boost Immunization with an Adenovirus Type-5 Vector-based COVID-19 Vaccine (Ad5-nCoV) After Three-dose Priming with an Inactivated COVID-19 Vaccine in Adults Aged 18 Years and Above: a Randomized, Open-label, Parallel-controlled Clinical Trial
Lead sponsor
Jiangsu Province Centers for Disease Control and Prevention
Phase
Phase 4
Overall status
Completed
Start date
April 23, 2022
Completion date
May 31, 2023
Enrollment
362 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19